Jump to main content
Jump to site search

Issue 11, 2016
Previous Article Next Article

Designing metallodrugs with nuclease and protease activity

Author affiliations

Abstract

The accidental discovery of cisplatin some 50 years ago generated renewed interest in metallopharmaceuticals. Beyond cisplatin, many useful metallodrugs have been synthesized for the diagnosis and treatment of various diseases, but toxicity concerns, and the propensity to induce chemoresistance and secondary cancers make it imperative to search for novel metallodrugs that address these limitations. The Amino Terminal Cu(II) and Ni(II) (ATCUN) binding motif has emerged as a suitable template to design catalytic metallodrugs with nuclease and protease activities. Unlike their classical counterparts, ATCUN-based metallodrugs exhibit low toxicity, employ novel mechanisms to irreversibly inactivate disease-associated genes or proteins providing in principle, a channel to circumvent the rapid emergence of chemoresistance. The ATCUN motif thus presents novel strategies for the treatment of many diseases including cancers, HIV and infections caused by drug-resistant bacteria at the genetic level. This review discusses their design, mechanisms of action and potential for further development to expand their scope of application.

Graphical abstract: Designing metallodrugs with nuclease and protease activity

Back to tab navigation

Publication details

The article was received on 09 Jun 2016, accepted on 20 Sep 2016 and first published on 20 Sep 2016


Article type: Minireview
DOI: 10.1039/C6MT00133E
Citation: Metallomics, 2016,8, 1159-1169
  •   Request permissions

    Designing metallodrugs with nuclease and protease activity

    C. M. Agbale, M. H. Cardoso, I. K. Galyuon and O. L. Franco, Metallomics, 2016, 8, 1159
    DOI: 10.1039/C6MT00133E

Search articles by author

Spotlight

Advertisements